This concept paper outlines BioPhorum’s considerations regarding Anvisa’s intention to adopt WHO guidelines while meeting the related ICH ones. The paper demonstrates how national regulatory agencies and biomanufacturers can make use of both guidelines and introduces the desired principles for national regulations.
